Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Maschmann, Raíra Mesquita; Jesus, Rafaela Gomes de; Werutsky, Gustavo; Rebelatto, Taiane Francieli; Queiroz, Geraldo Silva; Simon, Sérgio Daniel; Bines, José; Barrios, Carlos H.; Rosa, Daniela Dornelles

doi:10.1007/s10549-022-06809-8

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To understand the impact of MammaPrint™ in Brazil, we consider that there are an estimated 73,610 new cases of breast cancer each year (INCA 2023) [ 29 ], and according to data from AMAZONA 3 [ 24 ], 40.65 % would be stage II and 54.55 % with a Luminal profile, and according to the AGEMA-BRA study 66.9 % of this population would be aged ≥50 years; therefore 14.8 % of these patients could benefit from the use of MammaPrint™, or 10,894 women with breast cancer would be tested, leading to a reduction in chemotherapy for approximately 6,514 patients, 70 % of whom would be treated in the public sector. In a macroeconomic analysis, the potential cost savings could have a significant impact on the allocation of resources for public policies, especially in developing countries, and on the socioeconomic impact more broadly.…”

Section: Discussionmentioning

confidence: 99%

Impact of the genomic signature of 70-genes for breast cancer in the public system and in supplementary health care in a country of medium socioeconomic development

Mansani,

Soares,

Freitas Junior

2024

The Breast

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of the genomic signature of 70-genes for breast cancer in the public system and in supplementary health care in a country of medium socioeconomic development

Mansani,

Soares,

Freitas Junior

2024

The Breast

View full text Add to dashboard Cite

“…Timely access to proper treatment continues to be an issue in Brazil. The time interval between diagnosis and treatment of BC and the impact of health insurance coverage were analyzed in a cohort from the AMAZONA III study, with 1,709 stage I–III patients 20 . The diagnosis-to-treatment interval was higher in women treated in the public versus in the private system (56 vs. 34 days, p<0.0001), independent of clinical stage, type of treatment (systemic vs. surgery upfront), subtype, and country region 20 .…”

Section: Barriers To Disease Control and Strategies To Overcome Itmentioning

confidence: 99%

“…The time interval between diagnosis and treatment of BC and the impact of health insurance coverage were analyzed in a cohort from the AMAZONA III study, with 1,709 stage I–III patients 20 . The diagnosis-to-treatment interval was higher in women treated in the public versus in the private system (56 vs. 34 days, p<0.0001), independent of clinical stage, type of treatment (systemic vs. surgery upfront), subtype, and country region 20 . According to the Panorama of Gynecologic Cancer in Brazil, the time to start treatment after having a confirmatory biopsy is over 30 days in more than 70% of gynecologic cancer patients.…”

Section: Barriers To Disease Control and Strategies To Overcome Itmentioning

confidence: 99%

Breast and gynecologic cancers as a Brazilian health priority

Nogueira-Rodrigues

Rosa

Suzuki

et al. 2023

Rev. Assoc. Med. Bras.

Self Cite

View full text Add to dashboard Cite

SUMMARY OBJECTIVE: Cancer imposes a profound burden on low- and middle-income countries where 65% of the global cancer deaths occurred in 2020. The objective of the present review was to describe female cancer epidemiology in Brazil, barriers to prevention, screening, and treatment, and to propose strategies to a better control. METHODS: For the process of literature search and scientific acquisition, we have utilized the terms “female cancer” AND “breast cancer,” AND “cervical cancer” AND “endometrial cancer” AND “ovarian cancer” AND “Brazil” in PubMed. References of the articles included in this review were manually searched in order to identify relevant studies on the topic. The official Brazilian epidemiology data were extensively analyzed at the governmental site www.inca.gov.br . RESULTS: Considering cases of breast and gynecologic cancers together, 105,770 new cases are expected to be diagnosed yearly, positioning female cancer as the highest cancer incidence in Brazil. Female breast cancer is the most common and the leading cause of death from cancer in the female population in all regions of Brazil, except in the North, where cervical cancer ranks first. Cervical cancer, a preventable disease, corresponds to the third-most common neoplasia in women, with higher incidences in the North and Northeast regions of Brazil. An upward trend has been observed in endometrial cancer incidence, a tendency that follows the increase of its two most common risk factors: population aging and obesity. Ovarian cancer currently occupies the eighth position among female cancers in Brazil, but it is the most lethal gynecologic cancer. The main strategies to reduce female cancer mortality rates are the reduction of inequalities in healthcare services and the early diagnosis of cases. The lack of a specific national cancer program results in a reactive and unplanned approach to healthcare provision, ultimately leading to suboptimal resource utilization and higher expenditure. CONCLUSION: Analyzed together, breast and gynecologic cancers correspond to the leading cause of cancer in Brazil. A heterogeneous group, female cancer includes diseases with a high primary and secondary prevention potential. The organization of a female cancer program in Brazil prioritizing primary and secondary prevention strategies, such as adequate mammography screening and human papillomavirus vaccination coverage, could significantly improve female cancer control in the country.

show abstract

Survival of patients with de novo metastatic breast cancer

Leite,

Fernandes,

Curado

et al. 2024

Mastology

View full text Add to dashboard Cite

Introduction: For the 2020-2022 trieniumm more than 2 million cases of breast cancer were estimated worldwide. De novo metastatic breast cancer is so called when metastasis is diagnosed at the same time as the primary tumor. It affects approximately 3.5 to 10% of breast cancer patients and only 25% of these will be alive after 5 years. Methods: We conducted a retrospective cohort study of women with de novo metastatic breast cancer treated at a single center from January 1, 2000 to December 31, 2012. Cases were identified in the Hospital Cancer Registry. Overall survival (OS) was estimated at 5 years with the Kaplan-Meier product limit, and the log-rank test was used to test differences between curves; Cox multiple regression and all tests were considered significant with p<0.05. Results: Of the 265 patients in the study, the estimated 5-year OS was 31.3%. There was a difference in survival according to the following: age group (p<0.046); having had breast surgery (p<0.001); having undergone chemotherapy simultaneously with radiotherapy, hormone therapy, targeted therapy or surgery (p<0.088); use of exclusive or multimodal hormone therapy (p<0.001); education (p<0.001); luminal tumors (p<0.003); and being treated between 2006 and 2012 (p=0.043). In the multiple model adjusted by age group and education, the following factors remained as predictors of a better prognosis: having undergone surgery (hazard ratio — HR=0.46, 95% confidence interval — 95%CI 0.32–0.66); luminal tumors (HR=0.34, 95%CI 0.23–0.50); and targeted therapy (HR=0.27, 95%CI 0.15–0.46). Conclusion: The risk of death in patients with de novo metastatic breast cancer was lower than in those undergoing local surgical treatment as part of multimodal treatment, as well as the luminal molecular subtype and the introduction of better systemic treatment strategies, such as target.

show abstract

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Cited by 6 publications

References 24 publications

Impact of the genomic signature of 70-genes for breast cancer in the public system and in supplementary health care in a country of medium socioeconomic development

Impact of the genomic signature of 70-genes for breast cancer in the public system and in supplementary health care in a country of medium socioeconomic development

Breast and gynecologic cancers as a Brazilian health priority

Survival of patients with de novo metastatic breast cancer

Contact Info

Product

Resources

About